



# Peli BioThermal Products Play Pivotal Part in Pandemic Response Successfully Saving Lives in Vaccine Rollout



**More than 163.5m doses of the COVID-19 vaccine stored and distributed by Movianto**

As part of its ongoing rapid response to the global pandemic Peli BioThermal, the life science industry's cold chain partner from discovery to distribution, has driven the deployment of hundreds of thousands of lifesaving COVID-19 vaccines worldwide.

Peli BioThermal has collaborated with leading logistics providers to ensure the safe storage and delivery of vital vaccines, helping to save countless lives globally.



**More than 87.4% of the UK's over 12s were, at least, double jabbed**

## COVID-19 COLD CHAIN CHALLENGES

As part of the global fight against COVID-19, Peli BioThermal partnered with Movianto UK in a mutual mission to meet the monumental challenge of ensuring the biggest vaccine rollout in the UK history was successful.

Public Health England – PHE (now UKHSA) tasked Movianto with the responsibility of providing the central storage of the UK's COVID-19 vaccine stock and to manage a network to distribute critical vaccines around the country and much further afield.



**More than 207,000 lives already saved**

The mammoth medical rollout of vaccines required collaborations with specialist logistics firm Movianto and specially selected temperature-controlled packaging providers, including Peli BioThermal.

This was to guarantee vast quantities of essential vaccines and boosters to combat COVID-19 could be delivered to a huge network of hundreds of NHS vaccination sites, including 267 hospital hubs, 204 centres run by pharmacies, 1036 GP run outlets and 117 mass vaccination centres across the UK and much further afield.




**More than 250,500 hospitalisations had been avoided**

The exceptional challenge to achieve the historic vaccine rollout required round the clock operations with Peli BioThermal playing a pivotal part in the unparalleled vaccine delivery challenge, spanning the world.



**Almost 47 million doses administered as part of the ongoing booster programme**



## VARYING VACCINE TEMPERATURE REQUIREMENTS



Images  
supplied by  
Movianto UK

### PANDEMIC RESPONSE

The government asked Movianto to develop the supply line and central storage arrangements for the UK's vaccination programme prior to the development and approval of vaccines to help combat COVID-19.

Movianto would need to collaborate with thermal packaging specialists, like Peli BioThermal, to be able to safely store and transport the vaccines to multiple various venues once the jabs were made available.

On 2 December 2020, the Pfizer-BioNTech COVID-19 vaccine was approved for use in the UK and became the first vaccine to be authorised anywhere in the world.

This was closely followed on 30 December by the Oxford-AstraZeneca vaccine. Subsequently, in January 2021, a third vaccine produced by Moderna, was also approved for use in the UK.

As part of the ongoing pandemic response in September 2021, the UK government announced accelerated plans for a programme of booster vaccines.

### PRODUCT INNOVATION & ADAPTATION

Paul Terry Sales Director - EMEA for Peli BioThermal said: "Developing effective COVID-19 vaccines was only part of the battle in the ongoing fight against the virus. It's imperative the cold chain is maintained during shipping and storage, ensuring approved vaccines can be deployed worldwide without effecting efficacy of any life-saving jabs.

"We are proud of the strong relationships we have with pharmaceutical and cold chain logistics companies. We innovated, developed, and adapted a number of our products to work with the temperatures that were initially required for the vaccines. Several of our products have since moved forward an evolutionary step to use dry ice in with their existing thermal control structure and insulation.

"We feel privileged to have played such an instrumental role in the world's recovery from the pandemic by providing lifesaving products for the shipment of vaccines and therapies being used against COVID-19."



## VARYING VACCINE TEMPERATURE REQUIREMENTS

### FIGHTING THE VIRUS - VACCINE ROLLOUT

Paul Wilkinson, President of Movianto UK, said: "At the start, we didn't even know the storage criteria; we weren't aware of what the volume would be, but we did know we'd have to do it at breakneck speed, and we knew people's lives would be relying on it."

To meet the varying requirements of the UK vaccine rollout, Movianto used temperature-controlled products from Peli BioThermal's innovative range and those of selected suppliers.

Wilkinson added: "With the Pfizer-BioNTech product, we had to develop the supply line and storage arrangements for a vaccine that was completely new to the world, which had to be stored and transported, in bulk and small quantities, at the staggeringly low temperature of -75°C.

"Then we had to accommodate another two new vaccines as well, in Moderna's, which is stored at -20°C, and AstraZeneca's, which is chilled, which was more like the vaccines available before the pandemic.

"The vaccines are valuable beyond imagination. They are the way we're saving lives, getting our economy back on track and our lives back to normality."

As part of its ground-breaking work during the pandemic, tens of thousands of shipper solutions from Peli BioThermal's broad portfolio of products were adapted to meet the varying temperature requirements of approved vaccines, including the initial need to store jabs at -75°C.



Prior to the pandemic, no rollout programme or a supply chain for a vaccine that needed to be stored at such deep frozen temperatures existed and subsequently needed to be created in an incomparable rapid response.

To ensure the safe delivery of vaccines to hundreds of locations and meet the varying temperature requirements of the three UK approved vaccines, an array of Peli BioThermal's advanced shipper solutions were utilised.

Peli BioThermal's Sherpa Systems™ dry ice shippers were deployed to deliver the deep frozen vaccines and the company's CoolGuard™ Advance and CoolGuard™ PCM products were also incorporated in the ongoing vaccine rollout.



Images supplied by Movianto UK



## VARYING VACCINE TEMPERATURE REQUIREMENTS CONTINUED

Peli BioThermal's dedicated teams operated around the clock to ensure products were available to meet the colossal COVID-19 challenges and requirement for specialist shippers as part of the vaccine delivery operation.

The Sherpa Systems™ Dry Ice shipper was the most used product of the Peli BioThermal shippers selected by Movianto to ship the Pfizer vaccine; which had to be transported at -70°C, from their warehouses to vaccination centres across the United Kingdom. The Sherpa Systems is a simple but robust product, comprising an EPS (Expanded Polystyrene) container and lid, encased in a corrugate protective box.

From its UK base in Leighton Buzzard, Bedfordshire, Peli BioThermal supplied products to Movianto, between December 2020 and December 2021. To enable an order of this magnitude to be delivered on time and in full, Peli BioThermal ran three shifts a day over a 24 hour period for a number of weeks. To ensure delivery times / dates were met; suppliers, warehouse, production and logistics staff had to be completely focused on the necessity and importance of the project.

Movianto provided transport to take the finished goods from Leighton Buzzard to their regional warehouses. This required close coordination between Movianto and Peli BioThermal to alleviate stock build up or unproductive downtime.

In addition to the UK vaccine deliveries, Peli BioThermal also supplied examples of its CoolGuard™ Advance S20M shipper, which was used to transport the Moderna vaccine at -20°C. Another product used was the CoolGuard™ PCM shipper, used to transport the AstraZeneca vaccine at +2°C to +8°C to British Overseas territories, which included Gibraltar and Antarctica amongst others.

## VACCINE ROLLOUT RESULTS

As various vaccines were developed and approved for use, the temperature requirements evolved. Thermal packaging solutions, including pioneering products designed by Peli BioThermal, were critical in the rollout of vaccines and boosters.

As the subsequent booster campaign was ramped up, the requirements for robust thermal packaging became paramount.

Thousands of Peli BioThermal shippers selected by Movianto have been utilised as part of this phenomenal pandemic response, which has seen vaccines deployed to all the Crown dependencies (of the Isle of Man, Jersey, and Guernsey) alongside all UK Overseas Territories including Gibraltar, the Falkland Islands and regions as remote as Antarctica.



[Learn more](#) about our CoolGuard™ Advance product range



[Learn more](#) about our CoolGuard™ PCM product range

FOR MORE INFORMATION ABOUT PELI BIOTHERMAL PRODUCTS, PLEASE CONTACT:

EMEA OFFICE - [INFOEMEA@PELIBIOTHERMAL.COM](mailto:INFOEMEA@PELIBIOTHERMAL.COM) T: +44 (0)1525 243 770

AMERICAS OFFICE - [INFOAMERICAS@PELIBIOTHERMAL.COM](mailto:INFOAMERICAS@PELIBIOTHERMAL.COM) T: +1(763) 412-4800 TOLL FREE US: T: +(877) 537-9800

ASIA OFFICE - [INFOASIA@PELIBIOTHERMAL.COM](mailto:INFOASIA@PELIBIOTHERMAL.COM) T: +65 6681 0095

[PELIBIOTHERMAL.COM](http://PELIBIOTHERMAL.COM)

ISO17025, ISO9001-2008 Accredited

Golden Hour™, TIC™, Crêdo™, Crêdo Cube™, Crêdo ProEnvision™, Crêdo Xtreme™, Crêdo Duracube™, Crêdo ProMed™, Sherpa Systems™, CoolGuard™ and CoolPall™ are registered trademarks of Pelican Products Inc., its subsidiaries and / or affiliates



©2022 Peli BioThermal Ltd all rights reserved